

Article @ Virology

Decade Analysis of Rabies Vaccine for Human Use in China from 2011 to 2020

*Yunpeng Wang, Jia Li, Leitai Shi, Shouchun Cao**

National Institute for Food and Drug control, Beijing 102629, P.R. China

ABSTRACT

Objective: To analyze the marketing situation of rabies vaccine for human use in China in ten years. **Methods & Results:** The batch release data of rabies vaccine for human use from 2011 to 2020 were summarized and analyzed according to the official open data by the national institute for food and drug control (NIFDC). In the past ten years, the annual maximum number of issued was 17.7 million dose for one person, the annual minimum number of issued copies was 10.7 million dose for one person, and the average was 14.7 million dose. The main types of rabies vaccines for human use are Vero cell matrix, hamster kidney cell matrix, human diploid cell matrix and chicken embryo cell matrix, and chicken embryo fine cell matrix is produced by Chiron Behring Vaccines Private Ltd(India). In the past ten years, the production of human rabies vaccine Vero cells was dominated, such as it can be accounting for about 89.7% of the market in the years of 2020. **Conclusion:** The market situation of human rabies vaccine for the past decade is stable, and the average annual quantity which can be basically meet the market demandis was about 15 million dose for one person. At present, rabies vaccines for human use in China are mainly produced by domestic vaccine manufacture.

Copyright©2012-2025 Published by Hong Kong Institute of Biologicals Standardization Limited. All rights reserved.

Article history: Submitted: 18/11/2021; Revised: 16/12/2021; Accepted: 21/12/2021

DOI:10.21092/jav.v10i4.97

Key Words: Rabies Vaccine; Decade Analysis; Chinese Markting.

* Corresponding author, Major in the Immunology

E-mail: cao1976@hotmail.com